Senator has questions on Amgen anemia drug rebates
Reuters, April 4, 2008
Sen. Charles Grassley is questioning Amgen Inc. regarding allegations that some doctors received higher rebates on purchases of the company's anti-anemia drug Aranesp. In a statement, Grassley said there were concerns doctors were profiting by getting reimbursements from the government and private insurers that were higher than their actual cost for Aranesp. The drug is currently under scrutiny for safety concerns.
- How Medical Debt Forgiveness Benefits Hospitals
- Leapfrog Hospital Safety Scores 'Depressing'
- Patient Harm Data to Remain on Medicare's Hospital Compare Site
- Quiet ORs Better for Patient Safety
- Tavenner Confirmed as CMS Administrator
- Healthcare Leaders Sound Off on Organized Labor
- Building a Better Healthcare Board
- Esther Dyson's Population Health Dream
- CMS Seeks to 'Rapidly Reduce' Medicare Spending with $1B in Grants
- Rural Healthcare Can Entice the Best and Brightest